Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Work In Process (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of Work In Process data on record, last reported at $5.0 million in Q4 2025.

  • For Q4 2025, Work In Process rose 761.82% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, up 761.82%, while the annual FY2025 figure was $5.0 million, 761.82% up from the prior year.
  • Work In Process reached $5.0 million in Q4 2025 per ARQT's latest filing, up from $4.7 million in the prior quarter.
  • Across five years, Work In Process topped out at $5.0 million in Q4 2025 and bottomed at $116000.0 in Q3 2022.
  • Average Work In Process over 4 years is $1.5 million, with a median of $683500.0 recorded in 2024.
  • Peak YoY movement for Work In Process: skyrocketed 1158.47% in 2024, then crashed 66.0% in 2025.
  • A 4-year view of Work In Process shows it stood at $395000.0 in 2022, then rose by 23.04% to $486000.0 in 2023, then increased by 20.16% to $584000.0 in 2024, then surged by 761.82% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $5.0 million in Q4 2025, $4.7 million in Q3 2025, and $1.7 million in Q2 2025.